|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 4 (XETRA)
|
|
|
CA57808L3056
JP3801600002
GG00BMB5XZ39
US05875B3042
GB00BL97B504
CA92540L1076
CA04271V1058
GB00BN7JZR28
AU0000157075
PLAQUA000014
GB0001646941
CA31866G1028
KYG8116R1074
CA64082X2032
IT0005439861
JP3756200006
IT0005433765
PLDTLGM00019
PLCCTLS00017
SE0013382066
PLCNSLB00012
BE0974374069
US5632457033
KYG9482E1180
US04681Y1038
PLSNKTK00019
CNE100006M66
CA42804X3058
US3131488682
US3131488435
SE0000395428
FI4000592159
CA02255Q2099
IT0005531238
CA37895W1095
CA0029471095
AU0000284895
SGXE32143393
JP3049110004
SGXE32247038
US29081P2048
US0126532003
US00654J2069
CA0213618865
SE0009242175
AU000000ASX7
CNE1000001Y8
MHY3130D1013
GB00B95L0551
KYG9560F1028
KYG464401143
US6294442099
CA38154G1081
KYG4914A1076
CNE100007F98
US94858P2092
KYG1331C1042
US05969A1051
GRS001003052
US0970232049
US09260U1097
ARP125991090
US0773472016
AU0000153215
CNE100000551
SE0015961594
CNE100000254
US0905721082
IT0005468357
US09075P2048
GRS246003008
NZCENE0001S6
US05070F3082...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.12.25 - 07:03
|
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.09.25 - 07:03
|
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025....
|
|
|
|
|
|
|
|
|
|
|
19.06.25 - 08:24
|
Addex sieht sich nach Q1 auf gutem Weg (Moneycab)
|
|
|
Das Biotechunternehmen Addex ist gut in das neue Geschäftsjahr 2025 gestartet. Für den weiteren Geschäftsverlauf stehen dem Genfer Unternehmen liquide Mittel in Höhe von 2,8 Millionen Franken zur Verfügung....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
